glp-1 risk factors Long-Term Effects Of Medications: What You Should Know GLP-1 receptor agonists and gallbladder
Description
Fast, physician-guided results
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.
These medications exert (in)direct hepatic actions by reducing steatosis, attenuating inflammation, and potentially reversing fibrosis, while simultaneously addressing systemic metabolic abnormalities including excessive obesity, insulin resistance, and cardiovascular risk
Compared with SGLT-2 inhibitor use, GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration (pooled risk ratio 0.98, 95% CI 0.73 to 1.31), although it was associated with a higher risk for discontinuation of endoscopy (1.99, 1.56 to 2.53)
on the healthcare industry.
Schedule your consultation today!
